Abstract

BackgroundSlug is a transcription factor that activates the epithelial–mesenchymal transition (EMT) process in cancer progression. The aim of our study was to evaluate the clinical significance of Slug expression in gastric cancer.MethodsThe expression of Slug in gastric cancer tissues of 456 patients who underwent gastrectomy was evaluated by immunohistochemistry using tissue microarrays. Slug expression level was defined by the composite score determined by multiplying the tumor staining scores for intensity and extent. The associations of Slug expression with clinicopathological characteristics and overall and recurrence-free survival were analyzed.ResultsPatients were divided into three groups according to Slug composite score (≤4, 6, and 9). Low, mid, and high expression of Slug was observed in 104 (22.7%), 130 (28.3%), and 225 (49.0%) of cases, respectively. Overall survival and recurrence-free survival progressively increased from high to low Slug expression. In terms of lymph node metastasis, the rate of positive lymph node metastasis was 38/104 (36.5%), 79/130 (60.8%), and 178/225 (79.1%) in low, mid, and high Slug expression groups, respectively, displaying a tendency to increase with higher Slug expression. In a multivariate analysis adjusting for patient age, tumor size, tumor depth, and histology, high Slug expression was associated with a high rate of positive lymph node metastasis compared with low Slug expression (odds ratio 3.42; 95% confidence interval, 1.74–6.69). In a subgroup analysis of T1 cancer, patients with negative Slug expression (defined as <5% positive tumor cells or no/weak staining) showed no lymph node metastasis (0/13), whereas those with positive Slug expression showed 15.9% (17/107) lymph node metastasis, with a negative predictive value of 100%.ConclusionsHigh expression of Slug in gastric cancer tissue was associated with lymph node metastasis and poor survival. Evaluation of Slug would be useful for discriminating patients at high risk of lymph node metastasis in early gastric cancer.

Highlights

  • Slug is a transcription factor that activates the epithelial–mesenchymal transition (EMT) process in cancer progression

  • Classification of the patients according to Slug composite score yielded 104 (22.7%), 130 (28.3%), and 225 (49.0%) patients in the low, mid, and high Slug groups, respectively

  • High Slug expression according to our composite score was observed in about 50% of gastric cancer tissues

Read more

Summary

Introduction

Slug is a transcription factor that activates the epithelial–mesenchymal transition (EMT) process in cancer progression. Gastric cancer is the third leading cause of cancer death worldwide, and almost 1 million new cases occur annually [1]. With the introduction of mass screening methods such as endoscopy and upper gastrointestinal series, the proportion of patients with early detection of. Lee et al BMC Cancer (2017) 17:670 and metastasizes to regional lymph nodes. Differences in the prognoses of patients with negative lymph node metastasis versus positive lymph node metastasis are especially robust in surgically treated AGC [8,9,10]. EMT contributes pathologically to cancer progression by enabling primary tumor cells to break through the basal lamina and invade adjacent tissue, leading to tumor metastasis [14]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call